Eurofever分类标准与新版InFevers MEFV变异分类在真实世界中的影响:来自大型国际FMF队列的结果
基于Eurofever注册库中1012例家族性地中海热(FMF)患者,应用Eurofever/PRINTO分类标准(EPCC)和2018年INSAID的MEFV变异致病性分类,887例数据完整者中623例(70.2%)符合EPCC。EPCC阳性患者多具有典型FMF特征且秋水仙碱使用比例更高,EPCC阴性患者表型更多变、对秋水仙碱应答比例更低。
要点
- 887例数据完整患者中623例(70.2%)符合EPCC,264例(29.8%)不符合。
- EPCC阴性者中172例(65.1%)为阴性或非信息性遗传学结果。
- 基线秋水仙碱使用:EPCC阳性88% vs EPCC阴性69%(p < 0.0001)。
核心结论
- EPCC与2018年INSAID的MEFV变异分类联合应用可识别出临床特征、治疗方式和治疗应答不同的两组患者。
- EPCC阳性患者呈现典型FMF特征,EPCC阴性患者表型更多变且对秋水仙碱应答比例更低。
研究设计与样本
- 研究评估Eurofever注册库中FMF患者的基线人口学、遗传学和临床数据。
- 对所有符合条件的FMF患者应用EPCC和2018年INSAID的MEFV变异分类。
- 自2009年11月起,来自119个中心的1012例FMF患者(532例男性/480例女性,827例儿童/185例成人)有临床信息可用。
主要发现
- 887例数据完整患者中623例(70.2%)符合EPCC(EPCC+),264例(29.8%)不符合(EPCC-)。
- EPCC-患者中多数(172例,65.1%)为阴性或非信息性遗传学结果(单等位或双等位良性变异、单等位意义未明变异)。
- 基线时EPCC+患者多数使用秋水仙碱(88%),EPCC-患者使用比例较低(69%,p < 0.0001)。
- EPCC-患者按需使用激素或NSAID的比例更高(分别为p = 0.003和0.008)。
- 4%的患者接受了抗IL-1治疗。
关键数值与推荐
- EPCC阳性:887例中623例(70.2%);EPCC阴性:264例(29.8%)。
- EPCC阴性者中阴性或非信息性遗传学结果:172例(65.1%)。
- 基线秋水仙碱使用:EPCC+ 88% vs EPCC- 69%(p < 0.0001)。
- 按需激素使用EPCC-较EPCC+更高(p = 0.003);按需NSAID使用EPCC-较EPCC+更高(p = 0.008)。
- 抗IL-1治疗:4%的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: New Eurofever/PRINTO classification criteria (EPCC) for Familial Mediterranean Fever (FMF) and other recurrent fevers have been recently developed, together with the classification of the pathogenicity of MEFV variants. OBJECTIVES: To evaluate the impact in real life of both the EPCC and INSAID pathogenicity classification of MEFV variants in the large international Eurofever FMF cohort. METHODS: Baseline demographic, genetic and clinical data of FMF patients included in the Eurofever registry were evaluated. The EPCC and the 2018 INSAID classification for MEFV variants were applied in all eligible FMF patients. RESULTS: Since November 2009, clinical information was available for 1012 FMF (532 males/480 females, 827 children/185 adults) from 119 centres. Complete data were available for 887 patients in whom 623 (70.2%) satisfied EPCC (EPCC+), while 264 (29.8%) did not (EPCC-). The majority of the EPCC- patients (172, 65.1%) displayed negative or non-informative genetics (monoallelic or biallelic benign variants, monoallelic variant of unknown significance). At baseline, colchicine was used in most of EPCC+ patients (88%) and in a lower percentage of EPCC- patients (69%, p < 0.0001), who were treated in a higher proportion with steroid or NSAID on demand (p = 0.003 and 0.008, respectively). Four percent of patients received Anti-IL-1 treatment. CONCLUSIONS: The combination of EPCC and the 2018 INSAID classification of MEFV variants is able to identify two distinct groups of patients, which differ in clinical characteristics, therapeutic approach and response to treatment. EPCC+ patients displayed the typical features of FMF, while EPCC- patients had a more variable phenotype with a lower percentage of response to colchicine.
引用
- Bustaffa M, Koné-Paut I, Ozen S, et al. The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Semin Arthritis Rheum. 2022. PMID: 35042149. doi:10.1016/j.semarthrit.2022.151957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。